Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04720157
Other study ID # CAAA617C12301
Secondary ID 2020-003968-56
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 9, 2021
Est. completion date February 11, 2026

Study information

Verified date March 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants have been enrolled in 20 countries.


Description:

In this international, open-label, prospective, phase III study, where approximately 1126 patients with treatment naïve or minimally treated PSMA-positive mHSPC will be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617. The primary objective of the study is to determine whether the combination of 177Lu-PSMA-617 + SoC improves rPFS over that obtained by administration of SoC alone in mHSPC patients. The randomization will be stratified according to the following three factors: disease volume (high v low), age >= 70 years (yes/no), and on Previous or planned treatment (prostatectomy or radiation) to primary (prostate) tumor (yes/no). Study duration: approximately 50 months. screening period: after signing ICF, patients will be assessed for eligibility and will be scanned with 68Ga PSMA-11 to identify PSMA expression status. Following completion of all required screening procedures and verifying participant eligibility, the participant will be randomized via the interactive response technology (IRT) system. Amended protocol v02 included an option for participants to be enrolled into a separate long-term safety follow-up study, and China extension cohort (40 to 60 participants). Amended protocol v03 excluded China extension cohort and added a second 68Ga-PSMA-11 PET/CT scan at rPD. Prior treatment: - Up to 45 days of LHRH agonist/antagonists is allowed prior to ICF signature. If patient did not start the ADT prior randomization, ADT should start as soon as possible and ideally no later than 2 weeks after randomization. - Up to 45 days of ARDT is allowed prior ICF signature. If patient did not start the ARDT prior randomization, ARDT should start as soon as possible and ideally no later than 2 weeks after randomization. Patients will received ARDT as per label instructions. Randomization period: The participant will be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617. Treatment period: Patients randomized to the investigational arm (i.e. SoC+177Lu-PSMA-617): Patients will receive SoC as per label instructions, after randomization, if not started earlier and in the time frame allowed by the protocol. Patients must begin 177Lu-PSMA-617 dosing within 14 days after randomization or as soon as possible after the product is received. 177Lu-PSMA-617 is administered at the dose of 7.4 GBq (+/- 10%), once every 6 weeks (+/- 1 week) for a planned 6 cycles. Patients randomized to the control arm will begin receiving SoC as per label instructions after randomization, if not started earlier and in the time frame allowed by the protocol. The primary endpoint of rPFS will be assessed by a centralized blinded image review committee (i.e., BIRC) using radiographic images provided by the treating physician. Participants from both arms will also undergo PET/CT scan with 68GaPSMA-11 following Centrally confirmed rPD. An end of treatment (EOT) visit will be performed when participants permanently discontinue study treatment. Cross-over period: After patients randomized to the SoC alone (i.e., control) arm experience radiographic progression (the rPFS event) as confirmed by BIRC, they will be allowed to cross-over to receive 177Lu-PSMA-617 +/- SoC per the discretion of the treating physician. If cross-over to 177Lu-PSMA-617 is selected, then 177Lu-PSMA-617 will be administered with the same dose/schedule as participants who were initially randomized to receive 177Lu-PSMA-617 as described above. Study cross-over participants for whom 177Lu-PSMA-617 is discontinued must have a second End of Treatment (EOT2) visit performed =< 7 days and enter the Post-treatment Follow-up . Post-Treatment Follow-Up (Safety, Efficacy): After treatment discontinuation, all participants will be followed for safety with a 30-day safety follow-up visit (FUP) as well as longer term safety follow-up assessments for a period of approximately 12 months. Participants who discontinue study treatment without having progressive disease confirmed by BIRC, will continue to be assessed for efficacy (efficacy follow-up) during the post-treatment follow-up period until the occurrence of their BIRC-confirmed radiographic disease progression (rPFS) event , or if the total number of protocol-defined rPFS events has occurred triggering the primary analysis, whichever occurs first. Survival Follow-Up: After study treatment discontinuation, or post-treatment follow-up period discontinuation, the participant's status will be collected every 90 days (via phone calls) as part of the survival follow-up. Every effort should be made to comply with the survival follow-up schedule and ensure collection of participant survival. The survival follow-up and the study will end when the number of OS events required for final OS analysis will be reached.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1144
Est. completion date February 11, 2026
Est. primary completion date July 23, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: Participants eligible for inclusion in this study must meet all of the following criteria: 1. Signed informed consent must be obtained prior to participation in the study 2. Patients must be adults =18 years of age 3. Patients must have an ECOG performance status of 0 to 2 4. Patients must have a life expectancy >9 months as determined by the study investigator 5. Patients must have metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site) 6. Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan, and eligible as determined by the sponsor's central reader 7. Patients must have at least one documented metastatic bone and/or soft tissue/visceral lesion documented in the following manners within 28 days prior randomization: 1. Metastatic disease to the bone (in any distribution) visible on 99Tc-MDP bone scintigraphy on either pre-ADT scans or baseline scans AND/OR 2. Lymph node metastases of any size or distribution. If lymph nodes are the only site of metastasis, then at least one must be at least 1.5 cm in short axis AND outside of the pelvis AND/OR 3. Visceral metastases of any size or distribution. If a participant has a history of visceral metastases at any time prior to randomization, he should be coded as having visceral metastases at baseline (i.e., patients with visceral metastases prior to ADT that disappear at baseline will be counted as having visceral metastases and would therefore have high volume disease for stratification purposes). 8. Patients must have adequate organ function: - Bone marrow reserve ANC =1.5 x 109/L Platelets =100 x 109/L Hemoglobin =9 g/dL - Hepatic Total bilirubin =2 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome =3 x ULN is permitted Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =3.0 x ULN OR =5.0 x ULN for patients with liver metastases - Renal eGFR = 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation 9. Albumin =2.5 g/dL 10. Human immunodeficiency virus (HIV)-infected patients who are healthy and have a low risk of acquired immune deficiency syndrome (AIDS)-related outcomes can participate in this trial 11. Patients must be: Treatment naïve OR minimally treated with: - Up to 45 days of luteinizing hormone-releasing hormone (LHRH) agonist /antagonists or bilateral orchiectomy with or without first generation anti-androgen (e.g. bicalutamide, flutamide) for metastatic prostate cancer is allowed prior to ICF signature. If given, first generation anti-androgen must be discontinued prior to start of study therapy or after 45 days whatever happens first. - If received, prior LHRH agonist/antagonist with or without first generation anti-androgen use in the adjuvant/neo-adjuvant setting must have been discontinued > 12 months prior to ICF signature AND must not have exceeded 24 months of therapy AND must not have shown disease progression within 12 months of completing adjuvant/neo-adjuvant therapy. - Up to 45 days of CYP17 inhibitor or ARDT exposure for metastatic prostate cancer is allowed prior to ICF signature. No CYP17 inhibitor or ARDT exposure for earlier stages of prostate cancer is allowed. Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this study. 1. Participants with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy 2. Any prior systemic anti-prostate cancer therapy (with the exception of the drugs listed on inclusion criteria 11), including chemotherapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, immunotherapy or biological therapy (including monoclonal antibodies). 3. Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or investigational therapy 4. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed 5. Ongoing participation in any other clinical trial 6. Use of other investigational drugs within 30 days prior to day of randomization 7. Known hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes 8. Transfusion for the sole purpose of making a participant eligible for study inclusion 9. Participants with CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. Participants with epidural disease, canal disease and prior cord involvement are allowed if those areas have been treated, are stable, and not neurologically impaired. Participants with parenchymal CNS metastasis (or a history of CNS metastasis), that have received prior therapy and are neurologically stable, asymptomatic and not receiving steroids for CNS metastases, are allowed, baseline and subsequent radiological imaging must include evaluation of the brain (magnetic resonance imaging (MRI) preferred or CT with contrast). 10. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free, treatment free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible. 11. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. Participants with an active documented COVID-19 infection (any grade of disease severity) at time of informed consent may be included only when completely recovered (in accordance with local guidance). 12. Active clinically significant cardiac disease defined as any of the following: - NYHA class 3/4 congestive heart failure within 6 months prior to ICF signature unless treated with improvement and echocardiogram or MUGA demonstrates EF > 45% with improvement in symptoms to class < 3. - History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants in the study such as: Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block) - History of familial long QT syndrome or known family history of Torsades de Pointes - Cardiac or cardiac repolarization abnormality, including any of the following: History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature 13. History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study 14. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression 15. Any condition that precludes raised arms position 16. Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed. 17. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
177Lu-PSMA-617
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
68Ga-PSMA-11
Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
ARDT
Administered orally on a continuous basis as per package insert and guideline
ADT
ADT are administered as per physician order

Locations

Country Name City State
Austria Novartis Investigative Site Innsbruck Tyrol
Austria Novartis Investigative Site Linz
Austria Novartis Investigative Site Wien
Belgium Novartis Investigative Site Bruxelles
Belgium Novartis Investigative Site Gent
Canada Novartis Investigative Site Hamilton Ontario
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Sherbrooke Quebec
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Vancouver British Columbia
China Novartis Investigative Site Beijing
China Novartis Investigative Site Chengdu Sichuan
China Novartis Investigative Site Guangzhou
China Novartis Investigative Site Nanjing
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Shanghai Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Xian Shanxi
Czechia Novartis Investigative Site Olomouc CZE
Czechia Novartis Investigative Site Praha 5
Denmark Novartis Investigative Site Copenhagen
France Novartis Investigative Site Bordeaux Cedex
France Novartis Investigative Site Clermont-Ferrand
France Novartis Investigative Site Lyon
France Novartis Investigative Site Montpellier
France Novartis Investigative Site Nantes Cedex 1
France Novartis Investigative Site Paris
France Novartis Investigative Site Paris
France Novartis Investigative Site Strasbourg
France Novartis Investigative Site Vandoeuvre
France Novartis Investigative Site Villejuif
Germany Novartis Investigative Site Essen
Germany Novartis Investigative Site Koeln
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Muenster
Germany Novartis Investigative Site Rostock
Germany Novartis Investigative Site Wuerzburg
Japan Novartis Investigative Site Bunkyo ku Tokyo
Japan Novartis Investigative Site Chiba
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Fukuoka
Japan Novartis Investigative Site Fukuoka city Fukuoka
Japan Novartis Investigative Site Fukushima city Fukushima
Japan Novartis Investigative Site Kitaadachi-gun Saitama
Japan Novartis Investigative Site Kobe-city Hyogo
Japan Novartis Investigative Site Kumamoto City Kumamoto
Japan Novartis Investigative Site Kyoto
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Okayama-city Okayama
Japan Novartis Investigative Site Sapporo city Hokkaido
Japan Novartis Investigative Site Suita Osaka
Japan Novartis Investigative Site Yamagata
Japan Novartis Investigative Site Yokohama-city Kanagawa
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul
Korea, Republic of Novartis Investigative Site Seoul
Netherlands Novartis Investigative Site Delft
Netherlands Novartis Investigative Site Maastricht
Netherlands Novartis Investigative Site Nijmegen Netherland
Netherlands Novartis Investigative Site Utrecht
Poland Novartis Investigative Site Gliwice Slaskie
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Warszawa
Singapore Novartis Investigative Site Singapore
Singapore Novartis Investigative Site Singapore
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site El Palmar Murcia
Spain Novartis Investigative Site Hospitalet de LLobregat Catalunya
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Madrid
Spain Novartis Investigative Site Sabadell Barcelona
Spain Novartis Investigative Site Valencia
Sweden Novartis Investigative Site Goteborg
Sweden Novartis Investigative Site Lund
Sweden Novartis Investigative Site Stockholm
Switzerland Novartis Investigative Site Bern
Switzerland Novartis Investigative Site Lausanne
Taiwan Novartis Investigative Site Taipei
Taiwan Novartis Investigative Site Taoyuan
United Kingdom Novartis Investigative Site Belfast
United Kingdom Novartis Investigative Site Cambridge
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Middlesbrough Yorkshire
United Kingdom Novartis Investigative Site Sutton Surrey
United States University of New Mexico . Albuquerque New Mexico
United States Uni of Michigan Health System Ann Arbor Michigan
United States Uni Cancer and Blood Center, LLC Athens Georgia
United States Anschutz Medical Center Anschutz Medical Campus Aurora Colorado
United States Sidney Kimmel CCC At JH . Baltimore Maryland
United States Dana Farber Cancer Institute Dana-Farber Cancer Institute_ Boston Massachusetts
United States Montefiore Medical Center Bronx New York
United States Levine Cancer Institute Oncology Dept Charlotte North Carolina
United States University of Virginia Medical Center Charlottesville Virginia
United States Northwestern University Northwestern 6 Chicago Illinois
United States Rush University Medical Center . Chicago Illinois
United States University of Chicago Chicago Illinois
United States Cleveland Clinic Foundation . Cleveland Ohio
United States The Ohio State University Comprehensive Cancer Center . Columbus Ohio
United States Dallas VA Medical Center Dallas Texas
United States Texas Oncology Texas Oncology - Plano West Dallas Texas
United States Univ of Texas Southwest Med Center Dallas Texas
United States Duke Univ Medical Center . Durham North Carolina
United States Parkview Research Center . Fort Wayne Indiana
United States Hartford Hospital . Hartford Connecticut
United States Penn State Hershey Medical Center . Hershey Pennsylvania
United States Hines VA Hospital . Hines Illinois
United States The Queens Medical Centre Honolulu Hawaii
United States MD Anderson . Houston Texas
United States UT Health Science Center Houston Texas
United States Indiana University Simon Cancer Center Indianapolis Indiana
United States University of Mississippi Med Ctr . Jackson Mississippi
United States Cancer Specialists of North Florida Jacksonville Florida
United States Mayo Clinic Jacksonville Jacksonville Florida
United States University of California San Diego - Moores Cancer Center La Jolla California
United States Rocky Mountain Cancer Centers Rocky Mountain Cancer Centers Longmont Colorado
United States University Of California LA . Los Angeles California
United States VA Greater LA Healthcare System Los Angeles California
United States Baptist Health Medical Group . Miami Florida
United States University Of Miami . Miami Florida
United States Medical College of Wisconsin . Milwaukee Wisconsin
United States University of Minnesota Minneapolis Minnesota
United States Carolina Urologic Res Center, LLC Myrtle Beach South Carolina
United States Ochsner Clinic Foundation . New Orleans Louisiana
United States Tulane Cancer Center New Orleans Louisiana
United States Memorial Sloan Kettering Cancer Ctr New York New York
United States Weill Cornell Medical College New York New York
United States Virginia Oncology Associates . Norfolk Virginia
United States Nebraska Cancer Specialists Omaha Nebraska
United States Urology Cancer Center PC Omaha Nebraska
United States St. Joseph Hospital Center for Cancer Prevention Orange California
United States Univ Cali Irvine ALS Neuromuscular . Orange California
United States VA Palo Alto Health Care System . Palo Alto California
United States Florida Cancer Affiliates Panama City Florida
United States Thomas Jefferson Univ Hosp Philadelphia Pennsylvania
United States Univ of Pittsburgh Cancer Institute SC-3 Pittsburgh Pennsylvania
United States Oregon Health Sciences University . Portland Oregon
United States Onco Hemato Asso of SE Virginia Roanoke Loc Roanoke Virginia
United States Mayo Clinic Rochester Minnesota
United States Univ of Rochester Cancer Ctr . Rochester New York
United States Pharmacy Beaumont Hospital Royal Oak Michigan
United States St. Louis University . Saint Louis Missouri
United States VA St Louis Health Care System Saint Louis Missouri
United States Washington Uni School Of Medicine . Saint Louis Missouri
United States UT Health San Antonio Mays Cancer Center . San Antonio Texas
United States Sansum Clinic SC Santa Barbara California
United States Providence Saint Johns Health Ctr Santa Monica California
United States Mayo Clinic - Arizona Mayo Clinic Hospital Scottsdale Arizona
United States Swedish Medical Center . Seattle Washington
United States Stanford University Medical Center . Stanford California
United States Georgetown University Lombardi Washington District of Columbia
United States VA Medical Center Washington District of Columbia

Sponsors (3)

Lead Sponsor Collaborator
Novartis Pharmaceuticals Alliance Foundation Trials, LLC., RTOG Foundation, Inc.

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  China,  Czechia,  Denmark,  France,  Germany,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Singapore,  Spain,  Sweden,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Radiographic Progression Free Survival (rPFS) rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review, or death From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Secondary Overall Survival (OS) OS is defined as time to death for any cause From date of randomization until date of death from any cause, assessed up to 50 months (estimated final OS analysis)
Secondary Prostate-specific antigen 90 (PSA90) response PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary time to development of mCRPC Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases. From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
Secondary Progression Free Survival (PFS) PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Secondary second Progression Free Survival (PFS2) PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first. From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Secondary Change in nadir level of PSA lower than 0.2 ng/ml Proportion of patients with PSA < 0.2 ng/mL at months 12, 24 and 48 months From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
Secondary Time to radiographic soft tissue progression (TTSTP) TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR) From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Secondary Time to first symptomatic skeletal event (SSE). Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
Secondary Overall Response Rate (ORR) ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1 From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary Disease Control Rate (DCR) DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1 From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary Duration of Response (DOR) DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Secondary Time to Response (TTR) TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR). From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Secondary Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life. From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Secondary European Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L) EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions. From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Secondary Brief Pain Inventory-short Form (PBI-SF) The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use. From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Secondary Number of participants with Treatment Emergent Adverse Events The distribution of adverse events (AE) will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters. From randomization till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)
See also
  Status Clinical Trial Phase
Recruiting NCT04964271 - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed NCT02546908 - A Registry of Participants With Prostate Cancer in Asia
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT01683994 - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Completed NCT02364531 - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed NCT01929655 - Japanese BAY88-8223 Monotherapy Phase II Study Phase 2
Active, not recruiting NCT05022849 - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Phase 1
Completed NCT03261999 - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Phase 3
Terminated NCT04907227 - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension Phase 3
Active, not recruiting NCT03587285 - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT02217566 - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Phase 2
Not yet recruiting NCT04101305 - Measurement of Circulating Tumor Cells in Prostate Cancer
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Terminated NCT03066154 - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer Phase 1
Withdrawn NCT02905201 - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) N/A
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Terminated NCT01420965 - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Phase 2
Completed NCT01441713 - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer N/A